Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
Relief Therapeutics (RLFTF) has appointed Jack Weinstein as Chief Financial Officer ((CFO)) and Treasurer, effective immediately.Mr. Weinstein brings over 40 years of wide-ranging expertise. Before joining Relief, he served as Managing Director and Head of Healthcare Investment Banking at Ava...
Relief Therapeutics (RLFTF) and NeuroRx have established supply chain agreements and ordered sufficient drug substance (RLF-100) to prepare to treat 1M patients with COVID-19, should the pandemic continue. Relief and NeuroRx have now contracted with Nephron Pharmaceuticals to manufacture comm...
NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100™ (aviptadil) Development partners establish supply chain agreements and order sufficient drug substance to treat 1 million patients PR Newswire GENEVA and RADNOR, Pa., Sept. 3...
Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM GENEVA, SWITZERLAND / ACCESSWIRE / September 28, 2020 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead ...
NeuroRx has submitted a request for an Emergency Use Authorization ((EUA)) with the FDA for the use of RLF-100 aviptadil in patients who are receiving intensive care and have exhausted all approved treatments.RLF-100 is being developed by NeuroRx as part of a global partnership with Reli...
NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy Emergency Use Authorization request targets the same population as is currently...
FinancialBuzz.com News Commentary New York, NY (9/22/2020) – Due to increasing awareness amongst consumers on hygiene and preventive healthcare, the global surface disinfectant market is anticipated to grow significantly in the coming years. The current pandemic has caused major ...
Relief Therapeutics (RLFTF) and NeuroRx, Inc. have completed their partnership agreement for the commercialization of RLF-100 (Aviptadil) worldwide.The two organizations have agreed to share all profits from sales of RLF-100. NeuroRx will lead commercialization in the U.S., Canada, and I...
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100™ and Selection of Commercial Partners - RLF-100™ (Aviptadil) is in advanced stages of phase 2b/3 development in the US - Rapid recovery of patients on ventilators and ECMO (extracor...
Relief Therapeutics Holding AG ( OTCQB:RLFTF ) : 1H GAAP EPS of CHF0.004. More news on: Relief Therapeutics Holding AG, Earnings news and commentary, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
Mondobiotech Holding AG Basel Website:
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, ann...
GENEVA, SWITZARLAND / ACCESSWIRE / May 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Mee...
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...